On November 18, 2021 InnoCure Therapeutics reported that it has completed an international patent (Patent Cooperation Treaty, PCT) application for its Targeted Protein Degradation (TPD) drug (Press release, InnoCure Therapeutics, NOV 18, 2021, View Source [SID1234651742]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The substance for which Innocure has applied for a patent is a TPD drug that has been confirmed to have a decomposition effect on various target proteins using its own E3 ligase binder library platform technology, ELCBIL.

Unlike existing inhibitor drugs, TPD is a technology that directly decomposes and treats disease-causing proteins by utilizing the ubiquitin-proteasome system, a protein degradation pathway in the body.

InnoCure analyzed the animal efficacy of TPD drugs synthesized using its existing TPD development platform, TDbUM (Targeted Degradation by Ubiquitination Mediator), and its own Elkville platform technology. As a result, the company explained that it confirmed that tumor growth was inhibited in the TPD drug administration group compared to the control group.

Yoo Hye-dong, CEO of Innocure Therapeutics, said, "These TPD materials using the Elkville platform technology are significant in that they have superior decomposition efficacy and an advantage in securing IP compared to materials using E3 ligands used by existing companies." He added, "We will quickly proceed with preclinical studies on various TPD drugs using the Elkville platform technology."